Belatacept As an Alternative to Calcineurin Inhibitors in Patients with Solid Organ Transplants
The goal of immunosuppression in transplantation has shifted to improving long-term outcomes, reducing drug-induced toxicities while preserving the already excellent short-term outcomes. Long-term gains in solid organ transplantation have been limited at least partly due to the nephrotoxicity and me...
Main Authors: | Dhiren Kumar, Spencer LeCorchick, Gaurav Gupta |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2017-05-01
|
Series: | Frontiers in Medicine |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fmed.2017.00060/full |
Similar Items
-
Response: Commentary: Belatacept Does Not Inhibit Follicular T Cell-Dependent B-Cell Differentiation in Kidney Transplantation
by: Carla C. Baan, et al.
Published: (2018-03-01) -
Nephro and neurotoxicity of calcineurin inhibitors and mechanisms of rejections: A review on tacrolimus and cyclosporin in organ transplantation
by: Zahra Tolou-Ghamari
Published: (2012-04-01) -
Costimulatory Blockade and Solid Organ Transplantation: The Past, Present, and Future
by: William H. Kitchens, et al.
Published: (2023-12-01) -
A systematic review and meta-analysis comparing everolimus and calcineurin inhibitors (CNIs) to mycophenolate and CNIs in kidney transplant patients
by: Larraine Vergara-Rejante, et al.
Published: (2023-03-01) -
The use of belatacept in kidney transplantation
by: N. N. Babenko, et al.
Published: (2018-09-01)